# Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

> **NCT00044694** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 156 (actual)

## Conditions studied

- Diabetes Mellitus, Non-Insulin-Dependent

## Interventions

- **DRUG:** Placebo 0.01 mL
- **DRUG:** Placebo 0.02 mL
- **DRUG:** Placebo 0.03 mL
- **DRUG:** Placebo 0.04 mL
- **DRUG:** AC2993 2.5 mcg
- **DRUG:** AC2993 5.0 mcg
- **DRUG:** AC2993 7.5 mcg
- **DRUG:** AC2993 10.0 mcg

## Key facts

- **NCT ID:** NCT00044694
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2003-05
- **Final completion:** 2003-05
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2015-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044694, "Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00044694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*